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Renal, cardiovascular and hormonal characteristics of young adults
with autosomal dominant polycystic kidney disease. We studied young
adults with autosomal dominant polycystic kidney disease (ADPKD) to
determine the characteristics that precede renal impairment. Nineteen
affected (A) and 20 unaffected (U) offspring from families with ADPKD
showed no significant differences in basal glomerular filtration rate (A:
mean 97, SD 19; U: 100, SD 23 mlIminIl.73 m2) or renal functional
reserve, but effective renal plasma flow was significantly lower in
affected offspring (A: 532, SD 86; U: 605, SD 118 ml/minll.73 rn2, P <
0.01). Plasma renin activity [A: median 26 (95% Cl: IS to 37); U: 14 (Il
to 27) rU/m1, P < 0.05, one-tailed test] and aldosterone I A: 2.5 (2.0 to
3.0), U: 1.0 (1.5 to 2.0) g/l00 ml, P < 0.04, one-tailed testi were
increased in affected offspring despite the higher systolic blood pressure
(A: mean 123, SD 5; U: 115, SD 3 mm Hg, P < 0.02) and significant
expansion of total exchangeable sodium (A: 40.8, SD 2.3; U: 38.0, SD 3.5
mmol/kg, P < 0.01). The ouabain-sensitive component of red cell
sodium efflux was less in affected offspring (A: 0.258; SD 0.040; U:
0.288, SD 0.042 hr, P < 0.04) and in both groups was correlated
inversely with total exchangeable sodium. Echocardiography revealed
no difference in left ventricular mass index nor prevalence of mitral
valve prolapse. Potential cyst growth factors such as the glucocorti-
coids and somatomedin C were similar in both affected and unaffected
groups. Reduced renal blood flow, renin system activation and in-
creased body sodium precede the major clinical manifestations of
ADPKD and may play a central role in the genesis of high blood
pressure, and possibly also cyst growth, both of which are important
determinants of the clinical course of ADPKD.
Autosomal dominant polycystic kidney disease (ADPKD) is a
relatively common genetic disorder characterized predomi-
nantly by the growth of renal cysts, resulting in the appearance
of clinical symptoms in the fourth or fifth decades of life [.1, 2].
End-stage renal failure is a common, but not inevitable conse-
quence of ADPKD, and some studies suggest that the prognosis
of the condition may be improving [3, 4]. If this observation is
correct, then it may reflect an alteration in environmental
factors such as diet or the early detection of disease and
prevention of complications such as high blood pressure, that
modulate the impact of the primary genetic abnormality. The
characterisation of abnormalities at a stage before clinical
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manifestations are obvious may provide an understanding of the
disease process and form the basis for planning logical and
effective strategies to prevent or ameliorate the development of
renal failure in ADPKD.
Cyst growth, resulting in nephron obstruction and compres-
sion [51 has long been accepted as a specific major determinant
of renal failure in ADPKD. Studies of renal disease in general
have emphasized that glomerular hyperfiltration [6] and high
blood pressure [7] may cause non-specific acceleration of
kidney damage. At present, studies of glomerular filtration
reserve in ADPKD have received little attention [8]. In con-
trast, high blood pressure has received considerable attention
[1, 2, 9—15], although attempts to understand the pathogenesis
of high blood pressure in ADPKD have often been confounded
by important differences in age, blood pressure, renal function
and family history.
In this study we have attempted to minimize the effects of
common confounders by careful sampling, so as to focus on
early and possibly subtle abnormalities likely to be of relevance
to the development and progression of renal failure, in partic-
ular, glomerular hyperfiltration, high blood pressure and the
growth of cysts.
Methods
Subject selection and genetics
Families were identified from the Scottish registry of families
ascertained on the basis of one or more family members
diagnosed as suffering ADPKD. This registry contains 41 family
pedigrees with a total of 392 offspring and serves as a means of
identifying offspring at risk, providing routine testing for
ADPKD, including renal ultrasound examination and genetic
screening, and supplying information and educational material
for family members.
Offspring were eligible for participation if, at the time of the
study, they were between the ages of 16 and 35 years of age,
irrespective of serum creatinine or blood pressure. Subjects
were excluded if they suffered chronic illness (other than
ADPKD), were taking prescribed medication (excluding the
oral contraceptive pill) or were pregnant. These criteria resulted
in exclusion of only one eligible subject (who was affected) from
the families taking part because he had recently commenced
antihypertensive treatment.
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Offspring from 21 separate families took part in the study with
between one and five siblings (average 2.15) from each. Diag-
nosis of affected or unaffected status was based upon ultra-
sound findings. Ultrasonic criteria of the affected state were two
or more transonic cysts (>0.5 cm in diameter) with well-defined
back walls and some acoustic enhancement in one kidney, and
a single cyst in the other.
To complement ultrasound examination, genotypic studies
were performed with a probe for the 3'HVR region (the D16S85
locus near alpha globin on the short arm of chromosome 16) to
assess linkage to PKDJ [16]. Genetic risks were obtained using
the MLINK sub-routine of the program LINKAGE [17], For
these calculations it was assumed that heterozygous individuals
had probabilities of 0.22, 0.66, 0.86, 0.95 and 1.00 of clinical
detection in the age groups 0 to 9, 10 to 19, 20 to 29, 30 to 39 and
40+, respectively [181.
Pedigree studies revealed that all affected offspring came
from families showing linkage to PKDI, although two clinically-
affected offspring were considered genetic recombinants be-
cause of low calculated genetic risks. Disagreement between
clinical and genotypic diagnoses was relatively common in
three families that took part in this study. Careful review of
clinical data after completion of the study revealed that one of
these families (PK33) in fact did not have ADPKD, and the two
unaffected offspring from this family have been excluded from
all analyses. The two other families (PK49, PK53) from which
clinically unaffected offspring had been recruited did appear to
have ADPKD indistinguishable phenotypically from other par-
ticipating families.
Clinical protocol
Offspring were invited to participate in the physiological
studies by one investigator (AM) who was aware of their
diagnosis. Volunteers were asked specifically not to reveal their
diagnosis to the other investigators so as to avoid any potential
bias during the study. Selection was designed to provide equal
numbers of affected and unaffected offspring; subjects were
matched for age and sex.
Subjects were admitted to hospital on their normal diet for a
period of two days. Written informed consent was obtained
from all volunteers, and the studies were approved by the
Western Infirmary Ethics Committee.
On the first day, all subjects had echocardiographic exami-
nations using a Hewlett-Packard Ultrasound Unit with a 2.5
MFIz transducer. M-mode recordings were made according to
the convention of the American Society of Echocardiography
[19], with the use of two-dimensional images to direct the
M-mode sweep. These data were used to assess left ventricular
posterior wall thickness, interventricular septal thickness and
left ventricular diastolic diameter, measured distal to the tips of
the mitral valve leaflets at the peak of the R-wave on the
electrocardiogram. Measurements were made over three con-
secutive cardiac cycles, and mean values were calculated, Left
ventricular mass was calculated by the cube formula using the
Penn convention [20], and corrected for body surface area to
yield the left ventricular mass index. The reproducibility of
echocardiographic measurements in a single subject was calcu-
lated by measuring left ventricular mass on ten occasions in the
same healthy volunteer. The coefficient of variation was 2.9%.
Late systolic posterior displacement of the mitral valve echo
beyond an imaginary line joining the C and D portions of the
mitral valve echo was measured, and a displacement of greater
than 2.0 mm was taken to suggest mitral valve prolapse [21].
Two-dimensional echocardiographic studies were also per-
formed from the parasternal long-axis and apical four-chamber
views. These studies were recorded on tape and reviewed
subsequently for evidence of systolic "billowing" of the mitral
valve leaflets into the left atrium. The tapes were read indepen-
dently by two experienced echocardiographers who, in the
event of disagreement reached a consensus following joint
review of the study.
Subjects were fasted from 9 p.m. on the first day and
remained so, other than water during clearance measurements,
until the high-protein load at 12:30 p.m. on the following day.
On the morning of the second day subjects were woken at 7
a.m. and allowed out of bed briefly. Intravenous cannulae were
inserted into the right and left cubital veins. A blood pressure
cuff was then attached to the right arm, and blood pressure and
pulse rate were measured automatically every half an hour for
six hours, by a Copal UA251 Auto-Inflation Digital Sphygmo-
manometer (Takeda Medical Corporation, Japan) while the
subjects remained supine or semi-supine in bed. At the end of
each of these half-hour periods, three readings were taken and
averaged to calculate the systolic and diastolic blood pressure
and pulse rate for each period.
After the insertion of intravenous cannulae, the subjects
remained fully supine for 45 minutes, at the end of which time
blood was taken for biochemical, hematological and hormonal
tests, including plasma renin activity [22], atrial natriuretic
peptide [23], aldosterone [24], deoxycortisol and deoxycorti-
costerone [251, and cortisol and 18-hydroxycorticosterone
which were measured by direct radioimmunoassays following
partial purification by paper chromatography. The 18-hydroxy-
corticosterone antiserum was from Dr. H. Belkien (Klinikum
Sleglitz, Berlin, Germany). Somatomedin-C was measured us-
ing a radioimmunoassay kit (Nichols Institute Diagnostics, San
Juan, Capistrano, California, USA).
The dilutions of 24Na and 3H given about 19 hours before the
first blood sample were used to estimate, after correction for
overnight urinary isotope excretion, total exchangeable sodium
and body water, respectively [26—29]. To ensure adequate
tracer equilibration, dilution was remeasured in a second sam-
ple taken one hour later. The two estimates of total exchange-
able sodium and body water were not significantly different, and
individual values were calculated from the average of the two.
Identical conclusions were drawn from comparisons of affected
and unaffected offspring when exchangeable sodium was ex-
pressed either per kilogram of body weight, or as a percentage
of the expected normal value for a given surface area [28], and
for simplicity only the former data are presented. Plasma
volume was estimated from the dilution of a injected bolus of
'251-labelled albumin [29] and also expressed per kilogram body
weight.
Intraerythrocytic electrolyte concentrations and the total,
ouabain- and frusemide-sensitive transmembrane sodium efflux
constants were also measured. For sodium effiux measurements
a 6 ml aliquot of each subject's red blood cells (RBC) was
loaded with radiosodium by incubating with 25 Ci 24Na in 12
ml tissue culture fluid (TC199, Gibco Ltd, Paisley, Scotland,
UK) for four hours. Extracellular 24Na contamination was
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removed by three washes in cold TC199. Red blood cells (I ml)
were then resuspended in 1 ml IC 199, with or without ouabain
(l0— M) or frusemide (l0— M) and incubated at 37°C. This
mixture was sampled in triplicate at 8, 16 and 24 minutes after
addition of RBC. Each sample was centrifuged through oil at
13,000 g for 20 seconds, and immediately frozen in a mixture of
methanol and solid carbon dioxide. The radioactivity of the red
cell button and the extracellular fluid (ECF) were measured
separately, and the efflux rate constant (ERC) was calculated
from the natural logarithm of the radioactivity of the RBC (as a
percentage of RBC + ECF radioactivity) plotted against time.
Red cell sodium and potassium concentrations were measured
in RBC after triple washing in cold (4°C) isotonic choline
chloride and lysis in 15 mmol lithium chloride at known
hematocrit. Co-efficients of variation (3 estimates within 3
months in each of 12 normal subjects) were 4.8% for ERC, 5.4%
for ouabain-sensitive ERC and 4.0% for red cell sodium and
potassium concentrations.
Following initial blood sampling, standard constant infusion
clearance techniques were used to estimate glomerular filtration
rate and renal plasma flow [301, using inulin (50 g/50 ml,
Laevosan-Gesellschaft mbh, Linz, Austria) and PAH (2 g/lO
ml, MSD, West Point, Pennsylvania, USA), respectively. After
a loading dose of inulin (30 g/70 kg) and PAH (0.8 g/70 kg), half
of which was given as a rapid bolus injection and the rest over
about ten minutes, a constant infusion of inulin (0.96 g/hr) and
PAH (0.48 g/hr) was commenced. Each subject was given 5
mi/kg of water to drink at the time of the loading bolus, followed
by 1 mI/kg every half hour. One and a half hours were allowed
to ensure stable levels before estimating basal clearances based
on the known rate of infusion [30], and the plasma levels of
inulin [311 and PAH [32]. Three consecutive half-hour estimates
of glomerular filtration rate (GFR) and effective renal plasma
flow (ERPF) were averaged to provide basal control readings
for each individual.
The calculations used to derive ERPF assumed an extraction
ratio for PAH of 95%, and although we did not measure PAH
extraction ratio in this study, previous work [33] suggested that
in glomerular or tubulo-interstitial disease, the extraction ratio
does not change until PAH clearance rates are significantly
reduced (less than about half normal). Based on the observed
values of PAH clearance (see below) it seemed that PAH
extraction was a valid estimate of ERPF in this study.
To measure renal functional reserve and provide an indirect
assessment of glomerular hyperfiltration [34], at the end of the
control period all subjects were given a protein load (60 g/70 kg)
in the form of a drink of milk and soybean extract. Blood
pressure, pulse, GFR and ERPF were measured every half an
hour for a further two hours, until the end of the study.
Statistical analysis
Comparisons of variables between the two offspring groups
were made using CIA [35] and SPSS/PC+ [36], and where
possible the 95% confidence intervals for the differences be-
tween groups have been provided. The chi-square test was used
to compare sex distribution and the use of the oral contracep-
tive pill. Tests of statistical hypotheses were generally made
using two-tailed unpaired I-tests, but the variables plasma renin
activity, atrial natriuretic peptide, corticosteroids and so-
matomedin C did not show normal distribution and were
Table 1. Baseline characteristics of unaffected and affected offspring
from families with ADPKD
Unaffected Affected 95% CI
Number 20 19
Age years 26 (5) 24 (5) —2 to 5
Male:female ratio 10:10 9:10 —0.29 to 0.34
Oral contraceptive use 4 2 —0.19 to 0.59
Weight kg 68.8 (14.2) 66.2 (10.8) —10.8 to 5.6
Height m 168 (10) 172 (8) —1.6 to 10.2
Body surface area m2 1.77 (0.21) 1.78(0.16) —0.11 to 0.13
Results are mean (so). The 95% Cl is, for sex ratio and oral
contraceptive use, the 95% confidence interval for the difference
between proportions, and for all other variables, the 95% confidence
interval for the difference between means.
compared using the nonparametric Mann-Whitney U test. Stan-
dard regression analyses were used to analyze the relationship
between total exchangeable sodium and ouabain-sensitive
erythrocytic sodium efflux. Repeated measures analysis of
variance (MANOVA) was used to test for differences in systolic
and diastolic blood pressure, pulse rate and the absolute level
and change in GFR and ERPF after the protein load, and
whether the change in renal function or hemodynamics after the
protein load differed between affected and unaffected offspring.
Results
The twenty unaffected and 19 affected offspring were
matched in terms of sex, age, anthropometric measurements,
and use of the oral contraceptive pill (Table 1).
The results of routine hematological and biochemical screen-
ing were not significantly different in affected and unaffected
offspring. In particular, hemoglobin, hematocrit, plasma elec-
trolytes, urea. urate and liver function indices were similar in
the two groups (results not shown), Serum creatinine was the
same in both groups: unaffected, mean 80 mol/1iter (range 59
to 107); affected, mean 80 ,tmol/1iter (range 62 to 99).
Renal function and hemodynamics
Measurements of renal function showed that average basal
glomerular filtration rates were the same in the two groups
(Table 2). However, there was a substantial difference in renal
plasma flow; with average levels in affected offspring some 12%
lower than unaffected (Table 2).
Following the acute oral protein load, GFR rose significantly
by about 10 to 15% in both affected and unaffected offspring
(Fig. IA: MANOVA test of change in GFR with time: F434 =
13.8, P < 0.001). Although the GFR of unaffected individuals
remained slightly greater than that of affected offspring, the
overall difference was not significant throughout the study
(MANOVA test of GFR according to diagnosis: F137 = 0.57, P
= 0.454). The analysis also revealed that the rise in GFR after
the protein was similar in affected and unaffected subjects
(MANOVA test of interaction between diagnosis and change in
GFR with time: F434 = 1.07, P = 0.385).
Renal plasma flow also increased following the protein load
(Fig. lB: MANOVA test of change in ERPF with time: F434 =
5.5, P = 0.002). As seen during the control period, renal plasma
flow remained significantly lower in the affected offspring
following the protein load (MANOVA test of overall difference
in ERPF according to diagnosis: F137 = 11.1, P = 0.002).
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Table 2. Renal, fluid volume and electrolytic characteristics of unaffected and affected offspring from families with ADPKD
Unaffected Affected 95% CI
Glomerular filtration rate ml/min/l.73 m2 100 (23) 97 (19) —18 to 10
Effective renal plasma flow ml/min/1.73 m2
Exchangeable sodium mmol/kg
605 (118)
38.0 (3.5)
532 (86)"
40.8 (2.3)"
—140 to —5
0.9 to 4.8
Total body water mi/kg 573 (71) 594 (64) —22 to 62
Plasma volume mi/kg 39.6 (8.5) 41.7 (4.6) 2.4 to 6.6
Red cell sodium concentration mmol/iiter 5.7 (1.7) 5.2 (0.9) —1.3 to 0.4
Red cell potassium concentration mmoi/liter 104 (5) 100 (7) —7 to I
ERC, hr' 0.447 (0.062) 0.412 (0.065) —0.076 to 0.006
ERCOS hr'
ERCfS hr'
-
0.288 (0.042)
0.019 (0.009)
0.258 (0.040)'
0.020 (0.011)
—0.056 to —0.002
—0.008 to 0.006
Results are mean (SD). ERC,, ERCOS and ERC1S are the total, ouabain-sensitive and frusemide-sensitive components of the erythrocytic sodium
efflux rate constant. The 95% CI is the 95% confidence interval for the difference between means.
a p < b p < 0.005 compared to unaffected
90 I
30 60 90 120
I I
Control 30 60 90 120
Time, minutes
Fig. 1. (A) Giomeruiar filtration rate (GFR) and (B) effective renal
plasma flow (ERPF) in affected (•) and unaffected (fl) offspring before(control) and in the 2 hours after an acute oral protein load, Data are
presented as mean with SEM.
However, no important differences in the change of renal
plasma flow after the protein load were detected between the
two groups (MANOVA test of interaction between diagnosis
and change in ERPF with time: F434 = 1.15, P = 0.350).
Total exchangeable sodium was significantly elevated in
affected compared with unaffected offspring (Table 2). Average
total body water and plasma volume were also greater in
affected offspring, but the confidence intervals for the differ-
ences were relatively wide and included zero. Interestingly, the
average 2.8 mmol/kg difference in total exchangeable sodium
would be equivalent to an extra 20 mI/kg of extracellular water
(at the measured extracellular sodium concentration of 140
mmol/liter), which coincides well with the observed difference
in total body water, suggesting expansion of the extracellular
space.
Measurements of intracellular sodium and potassium and
transmembrane sodium efflux (Table 2) showed that although
erythrocytic intracellular electrolyte levels were similar, total
—
efflux rate constants for sodium were greater in unaffected
mm
offspring, and this appeared to result from lower rates of
ouabain-sensitive efflux in red cells of affected offspring.
Of particular interest was the observed relationship between
total exchangeable sodium and the ouabain-sensitive sodium
efflux rate constant, as shown in Figure 2. A negative correla-
tion between these two variables was observed in each group of
offspring, and the slopes (unaffected: —29.4, SE 18.2; affected:
—20.6, SE 13.2) and intercepts (unaffected: 46.5, SE 5.3; af-
fected: 46.2, SE 3.5) of the two regression lines were not
significantly different. When considered as a whole the regres-
sion of total exchangeable sodium (y) on ouabain-sensitive
efflux rate constant (x) was described by the formula: y
—33.6x + 48.6, r =
—0.445, (F137 9.11, P = 0.005).
Cardiovascular characteristics
The average systolic blood pressure was higher in affected
(mean 123, SD 13 mm Hg) than unaffected (115, SD 11 mm Hg)
offspring (95% confidence interval for difference = 1 to 15 mm
Hg, P < 0.02). Diastolic pressure levels tended to be higher in
affected (74, SD 9 mm Hg) than unaffected (71, SD 8 mm Hg)
offspring, but the confidence interval for the difference was
wide (95% CI: —3 to 9 mm Hg). The higher systolic blood
pressure of affected offspring was associated with a lower pulse
rate compared to unaffected individuals (60, SD 9 vs. 65, SD 7
min', 95% CI: —10 to 0, P < 0.02).
M-mode echocardiographic estimates of left ventricular mass
index did not reveal any significant difference between affected
(98, SD 28 g/m2) and unaffected (92, SD 21 g/m2) individuals (95%
CI: —12 to 23). Similarly, measurements of the degree of late
systolic prolapse of the mitral valve leaflets behind the C-D line
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Fig. 2. The relationship between total exchangeable sodium and the
ouabain-sensitive component of the total erythrocytic sodium efflux
rate constant in affected (U) and unaffected (0) offspring.
of the M-mode echocardiogram were on average, not different
between the two offspring groups. Nine subjects (3 affected, 6
unaffected) were detected with late systolic posterior displace-
ment of 2.0 mm or greater (none were greater than 3.0 mm),
suggesting the possibility of mitral valve prolapse. However,
analysis of 2-D echocardiograms revealed evidence of posterior
mitral valve leaflet prolapsing into the left atrium in only one of
the affected offspring and none of the unaffected subjects.
Hormonal measurements
Plasma renin activity and aldosterone were higher in affected
compared with unaffected subjects (Table 3). Because elevated
systolic blood pressure and total exchangeable sodium in af-
fected offspring might be expected to suppress the renin-
angiotensin-aldosterone axis, we tested the a priori hypothesis
that plasma renin activity and aldosterone was significantly
lower in affected than unaffected individuals and, therefore,
report the one-tailed P value in Table 3.
No significant differences of cortisol, corticosterone, deoxy-
cortisol, 18-hydroxycorticosterone, deoxycorticosterone or so-
matomedin C were observed between affected and unaffected
offspring (Table 3).
Discussion
In this study young adults with early ADPKD were compared
with unaffected offspring to identify characteristics that might
precede the development of, and possibly contribute to, the
progressive decline in renal function. Special care was taken in
designing the study to minimize potentially confounding effects
of differences in age, sex and family history.
Relatively narrow limits were set for age, not only to ensure
matching, but also to focus on a stage when measured variables
were not confounded by the presence of clinical complications
such as renal impairment and hypertension, although we ob-
served as reported previously [9], that affected offspring had
slightly higher levels of systolic blood pressure than unaffected
offspring.
Family history had an important bearing on the choice of
controls, as ADPKD families are not necessarily representative
of the community in general [371 and comparisons between
affected offspring and unrelated normal volunteers might be
confounded by such differences. For this reason unaffected
offspring were chosen as controls.
Diagnosis in young adults was established primarily by ultra-
sound, but we also sought to supplement clinical information
with genotypic studies, which proved more useful in assessing
families rather than individual subjects. We were able to
confirm that all affected offspring came from families in which
ADPKD was a result of inheritance of PKDI, which might be
important given the recent suggestion [38] of different clinical
manifestations in the minority of ADPKD families not showing
linkage to PKDJ. In our study two families (PK49, PK53)
showed relatively high rates of apparent recombination (2 out of
7, and 2 out of 5 informative meioses, respectively), and may be
families in which ADPKD is not linked to PKDI, although they
were not of sufficient size to positively confirm or deny this
possibility. By chance, only unaffected offspring were recruited
from these two families, and they did not differ substantially
from other unaffected offspring. Despite the care taken to
establish diagnosis, there remains the possibility that genetic
recombination and the delayed appearance of cysts might result
in genetically predisposed individuals having been classified as
unaffected. We cannot at the moment, gauge the extent of this
potential confounding effect.
In young adults, ADPKD did not appear to be associated with
detectable renal impairment. However, the demonstration of a
normal GFR did not, by itself, exclude the presence of glomer-
ular hyperfiltration, which has been suggested as responsible
for progressive decline in renal function in many forms of
kidney disease [6]. Nevertheless, we could find no evidence of
an inability of the affected kidneys to increase GFR in response
to an acute oral protein load, suggesting that, on average,
individual glomeruli are not operating at maximal filtration rates
in young adults with ADPKD. These findings are not altogether
unexpected as the cystic process does not involve primarily the
glomeruli, and it has been estimated only I to 2% of nephrons
contribute to the formation of cysts [5].
Some studies have reported that once renal functional decline
in ADPKD is obvious clinically, low protein diets slow the rate
of deterioration considerably [39], although others have shown
that protein restriction was ineffective [40]. However, our
findings would lend no support to the idea that normal basal
renal function in young adults with ADPKI) belies undetected
glomerular hyperfiltration that might justify the recommenda-
tion of low protein diets at this age.
Despite normal renal function, young affected offspring had
lower renal plasma flow and activation of the renin system. The
relationship between these two variables is likely to be com-
plex. Kidney blood flow might be compromized as a result of
the physical effects of intrarenal cysts, causing localized isch-
emia and renin secretion [41]. Renin may in turn exacerbate
effects on renal blood flow by causing intrarenal vasoconstric-
lion, as suggested by a recent report showing a large rise in
renal plasma flow after ACE inhibition in subjects with ADPKD
[41,42]. In addition to its effects on the renal vasculature, renin
may exert effects on the growth of intrarenal cysts, as one
recent study [43] observed that the rate of growth of experi-
mental renal cysts is increased when the renin system is
activated and reduced when renin is suppressed.
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Table 3. Hormonal characteristics of unaffected and affected offspring from families with ADPKD
Unaffected Affected 95% CI
Plasma ream activity jsU/ml 14.0(11.0, 26.5) 26.2 (14.5, 36.5)a —2.0 to 22.0
Atrial natriuretic peptide pg/mI 29.5 (22.0, 40.5) 34.0 (26.5, 50.0) —7.0 to 17.0
Aldosterone jsg/100 ml 2.0 (1.5, 2.0) 2.5 (2.0, 3,Q)a 0.0 to 1.0
Cortisol pg/100 ml 5.5 (4.5, 7.0) 4.5 (3.5, 6.0) —2.0 to 1.0
lI-deoxycortisol ng/100 ml 10.5 (6.5, 16.0) 13.0 (8.0, 26.0) —4.0 to 7.0
Corticosterone ng/J00 ml 255 (139, 357) 250 (134, 393) —126 to 143
18-hydroxy-corticosterone ng/100 ml 23.8 (17.0, 38.0) 36.0 (16.0, 44.5) —8.0 to 23.0
Deoxycortisone ng/l00 ml 8.5 (5.0, 12.0) 8.5 (4.5, 12.0) —4.0 to 4.0
Somatomedin C mU/mi 1.02 (0.79, 1.82) 0.77 (0.56, 1.11) —0.59 to 0.03
All values are expressed as median with the approximate 95% confidence interval of the median in parentheses. The 95% CI is the approximate
95% confidence interval for the difference in medians.
a P < 0.05 (one-tailed test) compared to unaffected
The increased total exchangeable sodium in affected offspring
is also likely to be the result of activation of the renin system,
and might explain the observed difference in systolic blood
pressure between affected and unaffected offspring. The ob-
served relationship between total exchangeable sodium and
ouabain-sensitive erythrocytic sodium effiux is interesting, and
may be indicative of some effect of body sodium on the level of
an endogenous inhibitor of the Na,K ATPase pump [44]. The
similarity of the relationship for both affected and unaffected
offspring suggests a general physiological link [44] between
body sodium and circulating inhibitors of Na,K ATPase. Pre-
sumably, renin-dependent sodium retention results in generally
higher levels of the endogenous inhibitor in affected offspring,
which may then have an effect on blood pressure [45, 46].
Despite the difference in systolic blood pressure between
affected and unaffected offspring, there was no evidence of
cardiac complications such as left ventricular hypertrophy or
mitral valve prolapse [47]. This contrasts with a recent report
[48] in a much wider age group, in which mitral valve prolapse
was especially prevalent in affected offspring, but also more
common in unaffected offspring than in the general population,
possibly because some families with ADPKD in that study also
harbored coincidentally a separate genetic predisposition to
mitral valve prolapse [49].
Much experimental evidence implicates corticosteroids in the
development and growth of renal cysts. Glucocorticoids have
been used to induce cyst growth in vivo [50, 51] and in vitro [51,
52], and the development of renal cysts in a murine genetic
model of polycystic disease [53] seems to depend on glucocor-
ticoids [54]. However, the present study revealed no abnormal-
ities of glucocorticoid metabolism in young adults with
ADPKD. Nevertheless, our data do not exclude the possibility
that glucocorticoids may have been abnormal at a younger age
and responsible for the genesis of renal cysts in affected infants,
although they do suggest that the continued growth of cysts in
adulthood is not dependent on elevated levels of glucocorti-
coids. The normal levels of somatomedin C in affected offspring
also imply that this growth factor is not responsible for the
growth of the cysts in young adults with ADPKD.
This study has characterized a group of apparently related
abnormalities in young adults with ADPKD that are likely to be
important steps in the development and progression of renal
disease. Renal failure is not an inevitable consequence of
ADPKD and sortie of these disease phenotypes, although
genetic in origin, could be modified by environmental changes
such as diet or pharmacological intervention. These matters
require further clinical scientific evaluation before any recom-
mendations are justified. The evidence of sodium retention
might lead to suggestions of salt restriction, but the resultant
rise in renin might adversely affect cyst growth [43]. In view of
the heightened activation of the renin system in young adults
with ADPKD, the effects of renin system antagonists on the
development of high blood pressure and the growth of cysts
requires further study. In the future, logical and well-tested
preventive strategies may significantly improve the clinical
impact of this important genetic condition.
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